Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy

Huizhe Wu; Yong Liu; Hui Kang; Qinghuan Xiao; Weifan Yao; Haishan Zhao; Enhua Wang; Minjie Wei

doi:10.1155/2015/279109

Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy

Biomed Res Int. 2015:2015:279109. doi: 10.1155/2015/279109. Epub 2015 Nov 8.

Authors

Huizhe Wu¹, Yong Liu², Hui Kang³, Qinghuan Xiao¹, Weifan Yao¹, Haishan Zhao¹, Enhua Wang⁴, Minjie Wei¹

Affiliations

¹ Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, China.
² Department of Clinical Laboratory, Shengjing Hospital of China Medical University, Heping Ward, Shenyang, Liaoning 110003, China.
³ Department of Clinical Laboratory, The First Hospital of China Medical University, Heping Ward, Shenyang, Liaoning 110001, China.
⁴ Institute of Pathology and Pathophysiology, The First Hospital and College of Basic Medical Sciences of China Medical University, Heping Ward, Shenyang, Liaoning 110001, China.

Abstract

The genetic variants of the ATP-binding cassette, subfamily G, member 2 (ABCG2) are known to be involved in developing cancer risk and interindividual differences in chemotherapeutic response. The polymorphisms in ABCG2 gene were genotyped by using PCR-RFLP assays. We found that ABCG2 G34A GA/AA genotype, C421A AA genotype, and haplotypes 34A-421C and 34G-421A were significantly associated with increased risk for developing breast carcinoma. Furthermore, ABCG2 C421A AA homozygote had a significant enhanced therapeutic response in patients with neoadjuvant anthracycline-based chemotherapy. Moreover, ABCG2 G34A AA genotype carriers displayed a longer OS in ER positive patients or PR positive patients after postoperative anthracycline-based chemotherapy. These results suggested that the ABCG2 polymorphisms might be a candidate pharmacogenomic factor to assess susceptibility and prognosis for breast carcinoma patients.

Publication types

Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

ATP Binding Cassette Transporter, Subfamily G, Member 2
ATP-Binding Cassette Transporters / genetics*
Adult
Aged
Aged, 80 and over
Anthracyclines / administration & dosage*
Antineoplastic Agents / administration & dosage
Biomarkers, Tumor / genetics*
Breast Neoplasms / drug therapy*
Breast Neoplasms / epidemiology
Breast Neoplasms / genetics*
China / epidemiology
Female
Genetic Predisposition to Disease / epidemiology
Genetic Predisposition to Disease / genetics
Genetic Variation / genetics
Humans
Incidence
Middle Aged
Neoplasm Proteins / genetics*
Polymorphism, Single Nucleotide / genetics*
Prognosis
Reproducibility of Results
Risk Factors
Sensitivity and Specificity
Treatment Outcome
Young Adult

Substances

ABCG2 protein, human
ATP Binding Cassette Transporter, Subfamily G, Member 2
ATP-Binding Cassette Transporters
Anthracyclines
Antineoplastic Agents
Biomarkers, Tumor
Neoplasm Proteins